Under AAAResearchReports.com Microscope: Celldex Therapeutics Inc., XOMA
Corp., Illumina Inc., and Immunomedics Inc.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, November 25, 2013
LONDON, November 25, 2013 /PRNewswire/ --
The U.S. equity market posted gains on Friday, November 22, 2013. The S&P 500
ended the day at 1,804.76, up 0.50%; the Dow Jones Industrial Average closed
at 16,064.77, up 0.34%; and the NASDAQ Composite finished at 3,991.65, up
0.57%. Shares in the biotechnology industry rose, tracking gains in the
broader market. The major movers in the industry included Celldex Therapeutics
Inc. (NASDAQ: CLDX), XOMA Corp. (NASDAQ: XOMA), Illumina Inc. (NASDAQ: ILMN),
and Immunomedics Inc. (NASDAQ: IMMU). AAAResearchReports.com has released full
comprehensive research on CLDX, XOMA, ILMN, and IMMU. These free technical
analyses can be downloaded by signing up at:
On Friday, Celldex Therapeutics Inc.'s stock rallied 8.51%, tracking gains in
the US equity market. The company's shares oscillated between $26.47 and
$29.43 before closing the day at $28.31. A total of 4.67 million shares were
traded, which is above the daily average volume of 2.91 million. The company's
shares have surged 20.01% in the previous three months and 17.23% in the last
three trading sessions, outperforming the S&P 500, which has gained 8.49% and
0.94% during the respective periods. Moreover, Celldex Therapeutics Inc.'s
stock is trading above its 50-day and 200-day moving averages of $27.45 and
$18.37, respectively. A free technical analysis on CLDX available by signing
XOMA Corp.'s stock surged 2.46% on Friday, closing the day at an intra-day
high of $4.16 after oscillating between $4.05 and $4.16 during the trading
session. A total of 0.62 million shares were traded, which is below the daily
average volume of 1.26 million. The company's shares have gained 8.62% in the
previous three trading sessions, outperforming the S&P 500, which has gained
0.94% during the same period. Additionally, XOMA Corp.'s stock is trading
above its 200-day moving average of $4.01. Register today and access free
research on XOMA at:
Shares in Illumina Inc. advanced 0.99% on Friday, hitting a new 52-week high
of $100.00. The company's shares closed the day at $99.83 after oscillating
between $98.02 and $100.00 during the trading session. A total of 0.97 million
shares were traded, which is below the daily average volume of 1.05 million.
The company's shares have surged 9.27% in the previous three trading sessions
and 25.87% in the last three months, outperforming the S&P 500, which has
gained 0.94% and 8.49% during the respective periods. Furthermore, Illumina
Inc.'s stock is trading above its 50-day and 200-day moving averages of $87.34
and $72.04, respectively. The free report on ILMN can be downloaded by signing
up now at:
On Friday, Immunomedics Inc.'s stock rallied to close the day at $4.45, up
14.10% from the previous day's closing price of $3.90. The company's shares
vacillated between $4.00 and $4.47 during the trading session. A total of 1.69
million shares were traded, which is above the daily average volume of 1.27
million. The company's shares have gained 21.88% in the previous three trading
sessions and 5.70% in the last one month, outperforming the S&P 500, which has
advanced 0.94% and 2.56% during the respective periods. Further, Immunomedics
Inc.'s stock is trading above its 200-day moving average of $4.20. A free
report on IMMU can be accessed by registering at:
1.This is not company news. We are an independent source and our views do
not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
only human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
increase awareness for mentioned companies to our subscriber base and the
4.If you wish to have your company covered in more detail by our team, or
wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
SOURCE AAA Research Reports
Contact: +1(646)396-9126, Peter F. Jones, email@example.com
Press spacebar to pause and continue. Press esc to stop.